Site icon pharmaceutical daily

Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids, 2019-2030 Markets – ResearchAndMarkets.com

BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Novel
Technologies for Delivery of Proteins, Antibodies and Nucleic Acids,
2019-2030” report has been added to ResearchAndMarkets.com’s
offering.

The Novel Technologies for Delivery of Proteins, Antibodies, and Nucleic
Acids, 2019-2030 report features an extensive study of the current
market landscape and the likely future adoption of such technologies,
over the next twelve years.

One of the key objectives of the report was to estimate the existing
market size and identify potential future growth opportunities for novel
technologies designed for the administration of proteins, antibodies,
and nucleic acids. Based on likely licensing deal structures and
agreements that are expected to be signed in the foreseen future, we
have provided an informed estimate on the evolution of the market over
the period 2018-2030.

The report features likely distribution of the current and forecasted
opportunity across the [A] type of therapeutic area (oncology and
non-oncology), [B] route of administration (parenteral and
non-parenteral), [C] key contributing technologies and [D] key
geographical regions (North America, Europe, Asia Pacific and rest of
the world). In order to account for future uncertainties and to add
robustness to our model, we have provided three market forecast
scenarios, namely conservative, base and optimistic scenarios,
representing different tracks of the industry’s growth.

The study features in-depth analysis, highlighting:

Key Topics Covered:

1. Preface

1.1. Scope of the Report

1.2. Research Methodology

1.3. Chapter Outlines

2. Executive Summary

3. Introduction

3.1. An Overview of Biopharmaceuticals

3.2. Demand for Biopharmaceuticals

3.3. Types of Biopharmaceuticals

3.3.1. Proteins and Peptides

3.3.2. Antibodies

3.3.3. Nucleic Acids

3.4. Common Routes of Administration for Biopharmaceuticals

3.4.1. Parenteral Delivery

3.4.1.1. Intravenous Route

3.4.1.2. Intramuscular Route

3.4.1.3. Subcutaneous Route

3.4.2. Non-Parenteral Delivery

3.4.2.1. Buccal / Sublingual Route

3.4.2.2. Intranasal Route

3.4.2.3. Inhalation / Pulmonary Route

3.4.2.4. Ocular Route

3.4.2.5. Oral Route

3.4.2.6. Rectal Route

3.4.2.7. Transdermal Route

3.5. Key Challenges Associated with Drug Delivery

3.6. Advanced Approaches for Delivery of Biotherapeutics

3.6.1. Muco-Adhesive Polymeric Systems

3.6.2. Nanoparticle-based Delivery Systems

3.6.3. Other Drug Delivery Technologies

3.7. Demand for Novel Drug Delivery Technologies

3.8. Concluding Remarks

4. Market Landscape

4.1. Chapter Overview

4.2. Novel Technologies for Proteins, Antibodies and Nucleic Acids:
Overall Market Landscape

4.2.1. Analysis by Size of Developer Company

4.2.2. Analysis by Year of Establishment

4.2.3. Analysis by Type of Technology

4.2.4. Analysis by Type of Biologics Delivered

4.2.5. Analysis by Impact of Technology on Drug Properties / Patient
Compliance

4.2.6. Analysis by Route of Administration

4.2.7. Analysis by Geographical Location of Developer Company

4.3. Grid Analysis: Distribution by Type of Biologics, Route of
Administration and Drug Delivery Parameters

4.4. List of Drug Formulation Technologies

5. Product Competitiveness Analysis

5.1. Chapter Overview

5.2. Product Competitiveness Analysis: Key Assumptions and Methodology

5.2.1. Technologies of Companies Based in North America

5.2.2. Technologies of Companies Based in Europe

5.2.3. Technologies of Companies Based in Asia-Pacific

6. Technology Profiles

6.1. Chapter Overview

6.2. Intravail Technology

6.3. RapidMist

6.4. TheraKine Technology

6.5. Arestat Technology

6.6. DelSiTech Silica Matrix

6.7. ImSus Technology

6.8. PLEX Technology

6.9. ENHANZE Technology

7. Company Profiles: Drug Delivery Platform Providers

7.1. Chapter Overview

7.2. Aphios

7.3. Arbutus Biopharma

7.4. Camurus

7.5. ConjuChem

7.6. InnoCore Pharmaceuticals

7.7. LATITUDE Pharmaceuticals

8. Patent Analysis

8.1. Chapter Overview

8.2. Scope and Methodology

8.3. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic
Acids: Patent Analysis

8.3.1. Analysis by Publication Year

8.3.2. Analysis by Issuing Authority / Patent Offices Involved

8.3.3. Analysis by CPC Classification

8.3.4. Emerging Focus Areas

8.3.5. Leading Players Based on Number of Patents

8.4. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic
Acids: Patent Benchmarking Analysis

8.4.1. Analysis by Patent Characteristics

8.4.2. Analysis by Geography

8.5. Novel Technologies for Proteins, Antibodies and Nucleic Acids:
Patent Valuation Analysis

9. Recent Partnerships

9.1. Chapter Overview

9.2. Partnership Models

9.3. Novel Technologies for Proteins, Antibodies and Nucleic Acids: List
of Partnerships and Collaborations

10. Market Sizing And Opportunity Analysis

10.1. Chapter Overview

10.2. Forecast Methodology and Key Assumptions

10.3. Novel Technologies for Delivery of Proteins, Antibodies and
Nucleic Acids: Information on Licensing Deals

10.4. Novel Technologies for Delivery of Proteins, Antibodies and
Nucleic Acids: Overall Market, 2019-2030

10.5. Novel Technologies for Delivery of Proteins, Antibodies and
Nucleic Acids: Distribution by Region, 2019 and 2030

10.6. Novel Technologies for Delivery of Proteins, Antibodies and
Nucleic Acids: Distribution by Therapeutic Area, 2019 and 2030

10.7. Novel Technologies for Delivery of Proteins, Antibodies and
Nucleic Acids: Market Attractiveness Analysis by Therapeutic Areas

10.8. Novel Technologies for Delivery of Proteins, Antibodies and
Nucleic Acids: Distribution by Route of Delivery, 2019 and 2030

10.9. Novel Technologies for Delivery of Proteins, Antibodies and
Nucleic Acids: Market for Key Contributing Technologies, 2019 and 2030

11. Future Growth Opportunities

11.1. Chapter Overview

11.2. The Industry Has Recently Witnessed A Shift from Conventional
Nanoparticle-Based Technologies to DNA-Based Solutions

11.3. Despite Extensive Research Efforts in this Domain, There is Still
A Substantial Unmet Need Related To Drug Delivery Technologies For
Neurodegenerative Disorders

11.4. The Oral Route of Delivery, Owing to its Capability to Ensure
Therapy Adherence, Has Garnered Significant Attention in this Market

11.5. Impending Patent Expirations Have Prompted Many Players to Adopt
Various Life Cycle Management Strategies to Sustain Revenue Generation
Potential

11.6. The Larger Market Share is Currently with the Developed Regions,
while Contributions from Technology Providers in the Asia Pacific are
Expected to Increase in the Foreseen Future

12. Executive Insights

12.1. Chapter Overview

12.2. ArmaGen

12.2.1. Company Snapshot

12.2.2. Interview Transcript: Mathias Schmidt, Chief Executive Officer

12.3. ICB International

12.3.1. Company Snapshot

12.3.2. Interview Transcript: Ram Bhatt, Chief Executive Officer,
Chairman and Founder

12.4. KAER Biotherapeutics

12.4.1. Company Snapshot

12.4.2. Interview Transcript: Donovan Yeates, Chief Executive Officer
and Chief Scientific Officer, Chairman and Founder

13. Appendix 1: Tabulated Data

14. Appendix 2: List Of Companies And Organizations

For more information about this report visit https://www.researchandmarkets.com/r/kkur78

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Biotechnology

Exit mobile version